fig5

Figure 5. Modulation of LNP carriers for overcoming cancer drug resistance. (A) The use of combination therapy of CTX-HSA-NPs and TGFβ-1 siRNA LNPs in PTX-resistant NSCLC. This figure is quoted with permission from Tan et al.^[32]; (B) The transmission electron microscopy (TEM) and scanning electron microscopy (SEM) images of CTX-HSA-NPs at ratios 6:1, 8:1, and 10:1. This figure is quoted with permission from Tan et al.^[32]; (C) LNP-miRs enhanced the efficacy of MAPKi therapy in xenograft melanoma models. The percentage of tumor reduction was determined relative to the initial volumes in mice injected with A375 or M14 from the groups treated with LNP-Scr + MAPKi or LNP-miRs + MAPKi. This figure is quoted with permission from Fattore et al.^[128]; (D) A versatile lipid-based nanoplatform for precise co-delivery of sorafenib and Midkine siRNA to hepatic cancer cells. This figure is quoted with permission from Younis et al.^[33]; and (E) Overview of mitigating anti-PD-1 resistance through STING-LNP. This figure is quoted with permission from Nakamura et al.^[134].